Publication

Article

Pharmacy Times

September 2012 Oncology
Volume79
Issue 9

Melanoma Condition Center Debuts

This month, we introduce a new condition center on www.PharmacyTimes.com covering melanoma, which accounts for approximately 5% of skin cancers, but is responsible for 3 times as many deaths as all other skin cancers combined. Once rare, melanoma’s incidence has increased along with people’s exposure to ultraviolet radiation from the sun.

Although anyone can develop melanoma, genetic factors can increase one’s risk, including having a light complexion, an inability to tan, red hair, blue eyes, or familial mole/melanoma syndrome. The first-line treatment for melanoma is surgical removal of the malignant lesion and a margin of healthy skin, but a number of medications play a role in treatment as well.

Some topics that will be covered in the melanoma condition center include:

  • A smartphone app that helps track moles that may indicate the development of melanoma
  • The discovery of a T-cell with the potential to help fight melanoma
  • The promise of combination therapy in treating melanoma

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com